HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: